Health Assessment of Weddell Seals, Leptonychotes weddellii, in McMurdo Sound, Antarctica

The demography of Weddell seals in eastern McMurdo Sound, Antarctica, has been well studied during the past three decades (e.g. Stirling 1971; Siniff et al. 1977; Testa and Siniff 1987; Hastings and Testa 1998; Gelatt et al. 2001). Detailed life-history data are available on thousands of seals tagged as pups in McMurdo Sound, making this population a rich resource for wildlife health studies because health parameters can be evaluated in the light of reproductive histories and genetic relationships of several generations of tagged seals. Recently, evidence of exposure to diseases generally associated with domestic animals and feral wildlife has been detected in Antarctic wildlife (Austin and Webster 1993; Olsen et al. 1996; Gardner et al. 1997; Retamal et al. 2000; Foster et al. 2002) and this has generated concern and debate regarding the risks of disease introduction to Antarctic wildlife. Antibodies to viruses that have caused large die-offs in phocids in other areas of the world have been detected in Weddell seals (Bengtson et al. 1991), and there is a historical report of a mass die-off of crabeater seals that may have had a viral etiology (Laws and Taylor 1957).

Review of issues concerning the use of reproductive inhibitors, with particular emphasis on resolving human-wildlife conflicts in North America

This manuscript provides an overview of past wildlife contraception efforts and discusses the current state of research. Two fertility control agents, an avian reproductive inhibitor containing the active ingredient nicarbazin and an immunocontraceptive vaccine, have received regulatory approval with the Environmental Protection Agency and are commercially available in the USA. OvoControl G Contraceptive Bait for Canada Geese and Ovo Control for pigeons are delivered as oral baits. An injectable immunocontraceptive vaccine (GonaCon Immunocontraceptive Vaccine) was registered with the Environmental Protection Agency for use in female white-tailed deer in September 2009. An injectable product (GonaCon Immunocontraceptive Vaccine) is registered for use in female white-tailed deer. Both products are labeled for use in urban/suburban areas where these species are overabundant. Several other compounds are currently being tested for use in wildlife in the USA, Europe, Australia and New Zealand that could have promise in the future. The development and use of reproductive inhibitors for resolving human–wildlife conflicts will depend on a number of factors, including meeting the requirements of regulatory agencies for use in the environment and on the biological and economical feasibility of their use. Use will also be dependent on health and safety issues and on public acceptance of the techniques.